DOVATO

DOSING

Visual of a man and woman talking, engaged in laughter together against a blurred background of a park setting. They are not actual patients

DOVATO Dosing

A Complete Single-Tablet Regimen Offering

One time, once daily icon One time, once daily icon

ONCE A DAY

Twenty-four hour icon Twenty-four hour icon

TAKEN ANY TIME OF DAY

Plate with and without food icon Plate with and without food icon

WITH OR WITHOUT FOOD

No booster icon No booster icon

BOOSTER FREE

USE IN SPECIFIC POPULATIONS (RENAL IMPAIRMENT)

DOVATO IS NOT RECOMMENDED IN PATIENTS WITH CREATININE CLEARANCE <30 mL/min. BECAUSE DOVATO IS A FIXED-DOSE TABLET, IT CANNOT BE DOSE ADJUSTED

A 30-Day Supply of DOVATO Is Available as an On-the-Go Blister Pack or in a Bottle

Image of DOVATO blister packaging Image of DOVATO blister packaging

Blister Packaging

NDC: 49702-246-33
Blister pack contains 4 sheets of 7 tablets and 1 sheet of 2 tablets for a 30-day supply. Packaging has perforations on each blister with 3- and 4-tablet portions and is smaller than a credit card.

Image of DOVATO bottle packaging Image of DOVATO bottle packaging

Bottle Packaging

NDC: 49702-246-13
Bottle contains 30 tablets for daily use.

Key Features of the DOVATO On-the-Go Blister Pack

Icon of DOVATO blister pack in wallet Icon of DOVATO blister pack in wallet

It’s small

Small in size, but big on discretion, it can be carried almost anywhere, providing convenience for whatever your patient’s day might bring

Icon of check mark Icon of check mark

Trackable dosing

Patients can monitor their remaining doses with just a glance at their blister strip

Icon of person on crosswalk Icon of person on crosswalk

On-the-go packaging

Blister strips with perforations that allow patients to take the amount of medication they may need with them, on the go

A 30-Day Supply of DOVATO Is Available as an On-the-Go Blister Pack or in a Bottle

Image of DOVATO blister packaging Image of DOVATO blister packaging

Blister Packaging

NDC: 49702-246-33
Blister pack contains 4 sheets of 7 tablets and 1 sheet of 2 tablets for a 30-day supply. Packaging has perforations on each blister with
3- and 4-tablet portions and is smaller than a credit card.

Key Features of the DOVATO On-the-Go Blister Pack

Icon of DOVATO blister pack in wallet Icon of DOVATO blister pack in wallet

It’s small

Small in size, but big on discretion, it can be carried almost anywhere, providing convenience for whatever your patient’s day might bring

Icon of check mark Icon of check mark

Trackable dosing

Patients can monitor their remaining doses with just a glance at their blister strip

Icon of person on crosswalk Icon of person on crosswalk

On-the-go packaging

Blister strips with perforations that allow patients to take the amount of medication they may need with them, on the go

Image of DOVATO bottle packaging Image of DOVATO bottle packaging

Bottle Packaging

NDC: 49702-246-13
Bottle contains 30 tablets for daily use.

Potential Drug Interactions With DOVATO

Established and Other Potentially Significant Drug-to-Drug Interactions

Avoid

Contraindicated

Dofetilide

Avoid Coadministration

Agent

Recommendations

Oxcarbazepine

Phenobarbital

Phenytoin

St. John’s wort (Hypericum perforatum)

Avoid coadministration with DOVATO because there are insufficient data to make dosing recommendations

Sorbitol

When possible, avoid use of sorbitol-containing medicines with DOVATO

Because DOVATO is a complete regimen, coadministration with other ARVs for the treatment of HIV-1 infection is not recommended.

Dosing Adjustments and Considerations

Agent

Recommendations

Carbamazepine or rifampin

An additional dolutegravir 50-mg dose should be taken, separated by 12 hours from DOVATO

Metformin

Refer to the Prescribing Information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin

Medications containing polyvalent cations (eg, Mg or Al): cation-containing antacids or laxatives, sucralfate, or buffered medications

Administer DOVATO 2 hours before or 6 hours after taking medications containing polyvalent cations

Oral calcium and iron supplements, including multivitamins containing calcium or iron

When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron

Dalfampridine

Elevated levels of dalfampridine increase the risk of seizures. The potential benefits of taking dalfampridine concurrently with DOVATO should be considered against the risk of seizures in these patients

Please see Section 7 of the full Prescribing Information for additional drug interaction information.

No Expected Dosing Adjustments1-7

Dolutegravir and lamivudine, components of DOVATO, have no clinically relevant effects on the pharmacokinetics of the following agents.

Based on available pharmacokinetics drug interaction studies

  • Prednisone
  • Midazolam
  • Rifabutin
  • Oral contraceptive containing norgestimate* and ethinyl estradiol
  • Proton pump inhibitors (omeprazole)

 

Based on pharmacokinetics, metabolic pathways, and/or available drug interaction studies

Hepatitis C drugs, including: 
  • Sofosbuvir
  • Ledipasvir/sofosbuvir
  • Elbasvir/grazoprevir
  • Ombitasvir/paritaprevir/ritonavir plus dasabuvir
  • Sofosbuvir/velpatasvir
  • Sofosbuvir/velpatasvir/voxilaprevir
  • Glecaprevir/pibrentasvir

*Norelgestromin is the active metabolite of norgestimate, and no drug interaction is expected with norgestimate.8

SEE IF YOUR PATIENTS CAN SAVE ON DOVATO

Al=aluminum; ARV=antiretroviral; Mg=magnesium; NDC=National Drug Code.

References:

1. AIDSinfo: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. US Department of Health and Human Services. Accessed February 7, 2023. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf 

2. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Updated May 24, 2018. Accessed March 2, 2022. https://www.hcvguidelines.org/unique-populations/hiv-hcv  

3. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2020. 

4. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 2022. 

5. Viekira Pak [package insert]. North Chicago, IL: AbbVie, Inc.; 2019.

6. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2019. 

7. Mavyret [package insert]. North Chicago, IL: AbbVie, Inc.; 2021. 

8. Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC. Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol. Ann Pharmacother. 2015;49(7):784-789. 

DLLWCNT230042 January 2024